Androgen receptor blockers are a growing acne research area because they target the root hormonal driver of breakouts — excess sebum triggered by androgens — rather than just managing symptoms with antibiotics or retinoids. The FDA approval of clascoterone 1% cream (Winlevi) in August 2020 marked a turning point: it was the first-ever topical androgen receptor inhibitor approved for acne, and it has since been prescribed more than 1.6 million times in the United States alone. That milestone proved the concept works, and now researchers are pushing further with next-generation compounds that don’t just block the androgen receptor but destroy it entirely. The shift matters because acne vulgaris affects approximately 9.4% of the global population and up to 50 million Americans each year, with over 85% of people aged 12 to 25 experiencing it at some point.
Despite decades of available treatments, the options have largely recycled the same mechanisms — kill bacteria, unclog pores, reduce inflammation. Androgen receptor blockers represent a genuinely new pathway, one that addresses why skin produces too much oil in the first place. The global acne therapeutics market, estimated at $9.06 billion in 2025 and projected to reach $11.51 billion by 2030, reflects the commercial appetite for better solutions. This article covers the science behind why androgens drive acne, how clascoterone performs in clinical trials, the emerging class of androgen receptor degraders in the pipeline, how systemic antiandrogens like spironolactone compare, the limitations you should know about, and what the next few years of research look like for this drug class.
Table of Contents
- Why Are Androgen Receptor Blockers Becoming Central to Acne Research?
- How Does Clascoterone (Winlevi) Perform in Clinical Trials?
- Next-Generation Androgen Receptor Degraders — Beyond Blocking
- How Do Topical Androgen Receptor Blockers Compare to Spironolactone?
- What Are the Limitations and Risks of Androgen Receptor Blockers?
- Cross-Platform Validation — What Hair Loss Trials Tell Us About Acne
- Where Androgen Receptor Blocker Research Is Heading
- Conclusion
- Frequently Asked Questions
Why Are Androgen Receptor Blockers Becoming Central to Acne Research?
Androgens are the most important hormones regulating sebum production, which is the primary driver of acne. Specifically, dihydrotestosterone (DHT) binds to androgen receptors in sebocytes — the cells that produce sebum — and switches on gene transcription that ramps up oil output and inflammatory cytokine production. Excess sebum clogs pores, feeds acne-causing bacteria, and triggers the inflammatory cascade that turns a clogged pore into an angry, red lesion. Every other acne treatment works downstream of this process. Androgen receptor blockers work at the source. What makes this research area particularly compelling is the topical delivery route. Systemic antiandrogens like spironolactone have been used off-label for years, but they come with systemic side effects including reduced libido, breast tenderness, and feminizing effects that make them unsuitable for male patients.
Topical androgen receptor blockers sidestep those problems entirely. Clascoterone competes directly with DHT for receptor binding at the skin level, without meaningful systemic absorption. This is a major reason approximately 65% of new acne product developments are now focusing on androgen receptor inhibitors, according to industry pipeline analyses. The practical difference is significant. A teenage boy with moderate acne has historically been limited to benzoyl peroxide, retinoids, and antibiotics. Systemic hormonal therapy was essentially off the table. Topical androgen receptor blockers opened a fourth lane, one that works for both sexes and all ages 12 and older. That broadened patient eligibility alone explains much of the research momentum.
How Does Clascoterone (Winlevi) Perform in Clinical Trials?
The clinical evidence for clascoterone comes primarily from two Phase 3 randomized controlled trials enrolling 1,440 patients total. After 12 weeks, clascoterone achieved treatment success rates of 18.4% versus 9.0% for vehicle in Study 1 and 20.3% versus 6.5% for vehicle in Study 2. These numbers may look modest at first glance, but the “treatment success” endpoint in acne trials is notoriously strict — it requires an Investigator Global Assessment score of 0 (clear) or 1 (almost clear) with at least a two-grade improvement. The lesion count reductions tell a fuller story: noninflammatory lesions dropped by 19.4 with clascoterone versus 13.0 and 10.8 with vehicle, and inflammatory lesions dropped by 19.3 and 20.0 versus 15.5 and 12.6 with vehicle. However, if you are expecting clascoterone to replace your entire acne regimen, that is not what the data supports. The effect sizes position it as a meaningful addition rather than a standalone cure.
Dermatologists are increasingly using it in combination with retinoids or benzoyl peroxide, where its unique mechanism of action — blocking the hormonal trigger rather than addressing bacteria or turnover — fills a gap that other topicals cannot. Think of it as addressing a different piece of the puzzle rather than solving the whole thing at once. One limitation worth noting: the UK did not approve Winlevi until early February 2025 through the MHRA, more than four years after the FDA cleared it. Regulatory timelines vary, and patients outside the U.S. have had to wait. Now that it is commercially available in the UK, broader real-world data from European and British populations should follow, which will help clarify how well clinical trial results translate to everyday use.
Next-Generation Androgen Receptor Degraders — Beyond Blocking
The most exciting development in this space is the emergence of PROTAC-based androgen receptor degraders, which represent a fundamentally different approach from clascoterone. Where clascoterone blocks the androgen receptor — essentially sitting in the receptor’s binding pocket so DHT cannot — PROTACs recruit E3 ubiquitin ligase to tag the entire androgen receptor protein for destruction by the cell’s own waste disposal system. The receptor is not just blocked; it is physically removed. In theory, this should produce a more complete and longer-lasting suppression of androgen signaling in the skin. GT20029, developed by Kintor Pharmaceutical, is the furthest along in this new class. It is a topically applied PROTAC compound that has completed Phase I studies for both acne and androgenetic alopecia, plus a Phase II trial for alopecia.
Another compound, AH-001, is also in clinical trials as a topically administered PROTAC androgen receptor degrader. Both are designed for skin application, maintaining the advantage of avoiding systemic side effects while potentially delivering stronger efficacy than receptor blockers alone. The practical question is whether degrading the receptor produces clinically meaningful improvements over simply blocking it. That data does not exist yet in published Phase 3 form. There is also the question of safety — completely eliminating androgen receptor signaling in skin cells, even locally, could have unintended consequences that only emerge over longer treatment periods. These compounds are promising, but they are still early-stage, and the leap from interesting mechanism to proven drug is long and littered with failures.
How Do Topical Androgen Receptor Blockers Compare to Spironolactone?
Spironolactone has been the go-to hormonal acne treatment for adult women for years, and recent evidence has only strengthened its case. A 2025 meta-analysis found that objective acne improvement was sixfold higher in the spironolactone group compared with placebo at doses of 50 to 100 mg daily. The randomized controlled FASCE study showed spironolactone delivered 1.37 to 2.87 times better treatment success compared with doxycycline at respective time points after six months — impressive numbers that outperform many topical options. But spironolactone has a hard ceiling: it remains off-label for acne and is limited to women. Its mechanism involves systemic androgen blockade, which means side effects like potassium elevation, menstrual irregularities, breast tenderness, and the risk of feminization that rules it out for male patients entirely.
For an adult woman with hormonal acne concentrated along the jawline and chin, spironolactone is often the more effective choice because it addresses systemic androgen levels rather than just local receptor activity. For a 15-year-old boy, or a woman who cannot tolerate the side effects, or anyone who prefers to avoid systemic medication, topical androgen receptor blockers fill a gap that spironolactone cannot. The tradeoff is clear: spironolactone is more potent but carries more risk and a narrower eligible population. Topical AR blockers are safer with broader applicability but currently deliver more modest efficacy. The research community’s bet is that next-generation topical compounds — particularly the PROTAC degraders — may eventually close that efficacy gap while maintaining the safety advantage of topical delivery. That is the prize driving much of the pipeline investment.
What Are the Limitations and Risks of Androgen Receptor Blockers?
The biggest limitation of current topical androgen receptor blockers is that not all acne is primarily androgen-driven. Acne is multifactorial — bacterial colonization, follicular hyperkeratinization, inflammation, and hormonal triggers all contribute in varying proportions depending on the patient. Someone whose acne is predominantly driven by Cutibacterium acnes overgrowth or abnormal skin cell turnover may see limited benefit from blocking androgen receptors. Clascoterone’s Phase 3 data showed that androgen receptor inhibitors produced 25% higher efficacy in adult female patients compared to other approaches, which makes sense given that hormonal acne is more prevalent in adult women. For adolescent males with primarily comedonal acne, the benefit may be less pronounced. There is also the practical challenge of adherence.
Clascoterone cream is applied twice daily, and like any topical, it only works where you put it. Patients with widespread body acne may find topical application impractical compared to a single daily pill. Cost is another barrier — Winlevi has faced insurance coverage inconsistencies since its launch, and without coverage, the out-of-pocket price can be prohibitive for a product that needs to be used continuously. A subtler concern involves long-term safety data. While the 12-week clinical trials showed a favorable safety profile, androgen receptors play roles in skin beyond just sebum production, including wound healing and hair growth. The 5% clascoterone solution currently completing Phase 3 trials for androgenetic alopecia — with regulatory submissions to FDA and EMA planned after 12-month safety data arrives in spring 2026 — will provide longer-duration safety data that the acne indication currently lacks. Until then, the long-term effects of chronic topical androgen receptor blockade remain an open question.
Cross-Platform Validation — What Hair Loss Trials Tell Us About Acne
One underappreciated aspect of the androgen receptor blocker story is how hair loss research is reinforcing the acne platform. Clascoterone 5% topical solution completed two pivotal Phase 3 trials in December 2025 for androgenetic alopecia — the largest trials ever conducted for a topical treatment of that condition. Because androgenetic alopecia and acne share the same underlying hormonal mechanism (DHT binding to androgen receptors in hair follicles and sebaceous glands, respectively), positive results in hair loss provide indirect but meaningful validation of the receptor-blocking approach for skin.
This cross-platform development also matters commercially. If a single compound can treat two high-prevalence conditions — acne and hair loss — through the same mechanism, the economics of research investment improve dramatically. The dual-indication strategy is part of why pharmaceutical companies are pouring resources into this class, and it gives clinicians more confidence that the mechanism is robust across tissues.
Where Androgen Receptor Blocker Research Is Heading
The next three to five years will be decisive for this drug class. The PROTAC degraders GT20029 and AH-001 will either advance through Phase 2 and 3 trials or fail, answering the question of whether receptor destruction outperforms receptor blockade in real patients. Spring 2026 will bring 12-month safety data from clascoterone’s alopecia trials, which will inform both regulatory decisions and the clinical community’s comfort level with prolonged topical androgen receptor modulation.
The broader market trajectory supports continued investment. With the acne therapeutics market growing at a 4.89% compound annual growth rate toward $11.51 billion by 2030, and with antibiotic resistance making traditional acne therapies less reliable over time, the demand for mechanistically novel treatments will only increase. Androgen receptor blockers are no longer a speculative concept — they are an approved, commercially validated drug class with a clear development pipeline. The question is no longer whether they work, but how much better the next generation can get.
Conclusion
Androgen receptor blockers have moved from theoretical promise to clinical reality. Clascoterone proved that topical androgen receptor inhibition is safe, effective, and viable for both sexes, earning more than 1.6 million prescriptions since 2020. The next wave — PROTAC-based degraders that eliminate the receptor entirely rather than just blocking it — could deliver meaningfully stronger efficacy while maintaining the safety advantages of topical delivery.
Meanwhile, systemic antiandrogens like spironolactone continue to show impressive results for adult women, with recent meta-analyses confirming sixfold improvement over placebo, but their inherent limitations in eligible patient populations keep the door open for topical alternatives. If you are dealing with acne and considering whether androgen receptor blockers might be relevant to your treatment plan, the most practical step is a conversation with a dermatologist about whether your acne pattern suggests a significant hormonal component. Jawline and chin-predominant breakouts in adults, acne that worsens with menstrual cycles, and acne that has not responded well to antibiotics or retinoids alone are all signals that an androgen-targeting approach may help. The science is moving fast in this space, and the options available today are substantially different from what existed even five years ago.
Frequently Asked Questions
Is Winlevi (clascoterone) available without a prescription?
No. Clascoterone 1% cream requires a prescription in both the United States and the United Kingdom. It is FDA-approved for patients aged 12 and older of both sexes.
Can men use androgen receptor blockers for acne?
Yes, and this is one of the key advantages over systemic antiandrogens like spironolactone. Because clascoterone works topically without significant systemic absorption, it avoids the feminizing side effects that make spironolactone unsuitable for male patients.
How long does it take for clascoterone to work?
The Phase 3 clinical trials measured outcomes at 12 weeks, and that is a reasonable timeframe to expect before assessing whether the treatment is working. As with most acne treatments, results are not immediate.
Are PROTAC androgen receptor degraders available yet?
Not yet. GT20029 and AH-001 are both in clinical trials but have not received regulatory approval. GT20029 has completed Phase I studies for acne and a Phase II trial for alopecia, but it likely has several years of development remaining before potential approval.
Can I use clascoterone with other acne treatments?
Clascoterone is generally used alongside other topicals like retinoids or benzoyl peroxide, as its mechanism of action is complementary. However, any combination regimen should be directed by a dermatologist, particularly to manage potential skin irritation from layering multiple active ingredients.
Is spironolactone better than clascoterone for hormonal acne?
For adult women with confirmed hormonal acne, spironolactone often delivers stronger results — a 2025 meta-analysis showed sixfold improvement over placebo. However, it requires systemic medication with associated side effects and monitoring. Clascoterone offers a topical alternative with fewer systemic risks, and the two are not mutually exclusive in a treatment plan.
